Gunnveig Grodeland

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK).

Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK).

Journal: Virus research
Published: March 13, 2026

Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).

Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).

Journal: Virus research
Published: March 13, 2026

An HLAII-targeted DNA vaccine against influenza H7N9 protected mice and ferrets from a virus challenge.

An HLAII-targeted DNA vaccine against influenza H7N9 protected mice and ferrets from a virus challenge.

Journal: NPJ vaccines
Published: July 25, 2025

DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection.

DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection.

Journal: Molecular therapy. Nucleic acids
Published: July 08, 2025

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease.

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease.

Journal: Clinical immunology (Orlando, Fla.)
Published: August 14, 2024

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.

Journal: The Lancet regional health. Europe
Published: August 05, 2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.

Journal: EBioMedicine
Published: January 31, 2024

An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models.

An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models.

Journal: Nature communications
Published: January 23, 2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.

Journal: RMD open
Published: July 28, 2023

Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients.

Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients.

Journal: EBioMedicine
Published: May 01, 2023

Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza.

Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza.

Journal: Journal of virology
Published: January 31, 2023

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.

Journal: NPJ vaccines
Published: January 25, 2023
Showing 1-12 of 48

Last Updated: 09/26/2026